PulseJournal ClubResearchersJournalsExplore
Instagram
HomeJournal ClubExplore
Synapse
⌘+K
Synapse
October 5, 2025Clinical review for general practiceOpen Access

Drug-induced interstitial lung injury in a patient with metastatic melanoma using a combination of nurulimab and prolgolimab

View Full Paper
Ask AI
Bookmark
Share

Authors

VCVladimir A. ChernorotovВБВ. А. БелоглазовВКВ. А. Кузнецов

Discussion

Loading...

Member takes

Overview

Clinical case presents drug-induced lung injury in a melanoma patient treated with monoclonal antibodies, suggesting the need for careful diagnosis.

Key Points

  • The case highlights the risk of pneumonitis from monoclonal antibody therapy in metastatic melanoma patients.
  • A 68-year-old woman exhibited drug-induced lung injury after treatment with Nurulimab and Prolgolimab.
  • Clinical observations indicate the importance of thorough medical history in diagnosing drug-induced lung injuries.
  • Immune-mediated side effects may result from therapy aimed at enhancing cytotoxic functions of immune responses.

Cite This Study

Chernorotov et al. (2025) studied this question.

synapsesocial.com/papers/68e24e60d6d66a53c2473264https://doi.org/10.47407/kr2025.6.7.00639
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Idiosyncratic Drug-Induced Liver Injury in a Patient With Metastatic Melanoma2025
  2. 2B80-6-15 When Immunotherapy Takes One Lung: A Rare Case of Unilateral Granulomatous Pneumonitis2026
  3. 3Drug-induced interstitial lung disease in lung cancer patients2025
  4. 4Late-Onset Immune-Mediated Hepatotoxicity Induced by the Immune Checkpoint Inhibitor Pembrolizumab in Lung Cancer: A Case Report2025
  5. 5Pembrolizumab-associated exacerbation of lichen planopilaris in a patient with metastatic melanoma2026